Antiestrogens: Mechanisms of action and resistance in breast cancer

被引:149
作者
Katzenellenbogen, BS
Montano, MM
Ekena, K
Herman, ME
McInerney, EM
机构
[1] UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA
[2] UNIV ILLINOIS, COLL MED, URBANA, IL 61801 USA
关键词
antiestrogens; tamoxifen; estrogen receptor; antiestrogen resistance; breast cancer; hormone sensitivity; endocrine therapy; resistance;
D O I
10.1023/A:1005835428423
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Antiestrogens have proven to be highly effective in the treatment of hormone-responsive breast cancer. However, resistance to antiestrogen therapy often develops. In addition, although tamoxifen-like antiestrogens are largely inhibitory and function as estrogen antagonists in breast cancer cells, they also have some estrogen-like activity in other cells of the body. Thus, recent efforts are being directed toward the development of even more tissue-selective antiestrogens, i.e. compounds that are antiestrogenic on breast and uterus while maintaining the beneficial estrogen-like actions on bone and the cardiovascular system. Efforts are also being directed toward understanding ligand structure-estrogen receptor (ER) activity relationships and characterizing the molecular changes that underlie alterations in parallel. signal transduction pathways that impact on the ER. Recent findings show that antiestrogens, which are known to exert most of their effects through the ER of breast cancer cells, contact a different set of amino acids in the hormone binding domain of the ER than those contacted by estrogen, and evoke a different receptor conformation that results in reduced or no transcriptional activity on most genes. Resistance to antiestrogen therapy may develop due to changes at the level of the ER itself, and at pre- and post-receptor points in the estrogen receptor-response pathway. Resistance could arise in at least four ways: (1) ER loss or mutation; (2) Post-receptor alterations including changes in cAMP and phosphorylation pathways, or changes in coregulator and transcription factor interactions that affect the transcriptional activity of the ER; (3) Changes in growth factor production/sensitivity or paracrine cell-cell interactions; or (4) Pharmacological changes in the antiestrogen itself, including altered uptake and retention or metabolism of the antiestrogen. Model cell systems have been developed to study changes that accompany and define the antiestrogen resistant versus sensitive breast cancer phenotype. This information should lead to the development of antiestrogens with optimized tissue selectivity and agents to which resistance may develop more slowly. In addition, antiestrogens which work through somewhat different mechanisms of interaction with the ER should prove useful in treatment of some breast cancers that become resistant to a different category of antiestrogens.
引用
收藏
页码:23 / 38
页数:16
相关论文
共 95 条
[1]  
ALLAN GF, 1992, J BIOL CHEM, V267, P19513
[2]   ROLE OF THE 2 ACTIVATING DOMAINS OF THE ESTROGEN-RECEPTOR IN THE CELL-TYPE AND PROMOTER-CONTEXT DEPENDENT AGONISTIC ACTIVITY OF THE ANTIESTROGEN 4-HYDROXYTAMOXIFEN [J].
BERRY, M ;
METZGER, D ;
CHAMBON, P .
EMBO JOURNAL, 1990, 9 (09) :2811-2818
[3]  
CASTLES CG, 1996, HORMONE DEPENDENT CA, P81
[4]   INTERACTION OF PROTEINS WITH TRANSCRIPTIONALLY ACTIVE ESTROGEN-RECEPTORS [J].
CAVAILLES, V ;
DAUVOIS, S ;
DANIELIAN, PS ;
PARKER, MG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (21) :10009-10013
[5]   SYNERGISTIC ACTIVATION OF ESTROGEN RECEPTOR-MEDIATED TRANSCRIPTION BY ESTRADIOL AND PROTEIN-KINASE ACTIVATORS [J].
CHO, H ;
KATZENELLENBOGEN, BS .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (03) :441-452
[6]   REGULATION OF PROGESTERONE-RECEPTOR GENE-EXPRESSION IN MCF-7 BREAST-CANCER CELLS - A COMPARISON OF THE EFFECTS OF CYCLIC ADENOSINE-3',5'-MONOPHOSPHATE, ESTRADIOL, INSULIN-LIKE GROWTH FACTOR-I, AND SERUM FACTORS [J].
CHO, HS ;
ARONICA, SM ;
KATZENELLENBOGEN, BS .
ENDOCRINOLOGY, 1994, 134 (02) :658-664
[7]   PROGRESSION OF HUMAN-BREAST CANCER-CELLS FROM HORMONE-DEPENDENT TO HORMONE-INDEPENDENT GROWTH BOTH INVITRO AND INVIVO [J].
CLARKE, R ;
BRUNNER, N ;
KATZENELLENBOGEN, BS ;
THOMPSON, EW ;
NORMAN, MJ ;
KOPPI, C ;
PAIK, S ;
LIPPMAN, ME ;
DICKSON, RB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3649-3653
[8]  
COHEN LA, 1975, LIFE SCI, V16, P107, DOI 10.1016/0024-3205(75)90213-1
[9]   IDENTIFICATION OF RESIDUES IN THE ESTROGEN-RECEPTOR THAT CONFER DIFFERENTIAL SENSITIVITY TO ESTROGEN AND HYDROXYTAMOXIFEN [J].
DANIELIAN, PS ;
WHITE, R ;
HOARE, SA ;
FAWELL, SE ;
PARKER, MG .
MOLECULAR ENDOCRINOLOGY, 1993, 7 (02) :232-240
[10]   ANTIESTROGEN ICI-164,384 REDUCES CELLULAR ESTROGEN-RECEPTOR CONTENT BY INCREASING ITS TURNOVER [J].
DAUVOIS, S ;
DANIELIAN, PS ;
WHITE, R ;
PARKER, MG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (09) :4037-4041